Inhibrx Biosciences, Inc. INBX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $124.22M-18.6% | $152.6M-45.1% | $277.92M+1.5% | ||
| $29.02M-13.5% | $33.54M— | —— | ||
| $132.83M-17.2% | $160.4M-45.7% | $295.36M— | ||
| $3.73M-39.8% | $6.2M-3.4% | $6.42M— | ||
| $11.12M+25.1% | $8.89M+33.0% | $6.69M— | ||
| 10.2%-733,799,990% | 733,800,000%+438,600,000% | 295,200,000%— | ||
| $4.38M-35.9% | $6.83M+116% | $3.16M— | ||
| $146.48M-19.0% | $180.77M-41.3% | $307.89M— | ||
| $29.9M-22.7% | $38.69M— | —— | ||
| $7.45M-75.1% | $29.89M-31.0% | $43.3M— | ||
| $2.33M+45.8% | $1.6M-22.7% | $2.06M— | ||
| $33.8M-17.0% | $40.73M-27.7% | $56.31M— | ||
| $100.56M— | $0-100% | $206.97M— | ||
| $4.13M-36.0% | $6.45M+481% | $1.11M— | ||
| $6.45M-19.8% | $8.05M+154% | $3.17M— | ||
| $138.49M+194% | $47.18M-82.2% | $264.39M— | ||
| $0— | $0— | $0— | ||
| 120M+11,999,900% | 1K-80.0% | 5K— | ||
| $254.18M+6.0% | $239.72M-63.5% | $657.23M— | ||
| -$246.19M-132% | -$106.13M+82.7% | -$613.73M— | ||
| $7.99M-94.0% | $133.58M+207% | $43.5M-25.1% | ||
| $146.48M-19.0% | $180.77M-41.3% | $307.89M— | ||
| $238K-37.7% | $382K+4.4% | $366K— | ||
| $177K-10.2% | $197K-67.5% | $607K— | ||
| $177K-10.2% | $197K-67.5% | $607K— | ||
| $4.38M-35.9% | $6.83M+116% | $3.16M— | ||
| $5.54M-24.6% | $7.34M+149% | $2.95M— | ||
| $5.54M-24.6% | $7.34M+149% | $2.95M— | ||
| $4.38M-35.9% | $6.83M+116% | $3.16M— | ||
| $14.85M-1.6% | $15.09M+15.2% | $13.11M— | ||
| $5.54M-24.6% | $7.34M+149% | $2.95M— | ||
| $4.38M-35.9% | $6.83M+116% | $3.16M— | ||
| $7.45M-3.6% | $7.73M+18.8% | $6.51M— | ||
| $25.53M-14.6% | $29.89M-31.0% | $43.3M— | ||
| $25.53M-14.6% | $29.89M-31.0% | $43.3M— | ||
| $7.45M-3.6% | $7.73M+18.8% | $6.51M— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| $447K-28.9% | $629K-19.4% | $780K— | ||
| —— | —— | —— | ||
| $107.01M+1,230% | $8.05M-96.2% | $210.14M— | ||
| $0.000.0% | $0.000.0% | $0.00— | ||
| 14.6M+0.7% | 14.5M-69.4% | 47.4M— | ||
| 15M0.0% | 15M0.0% | 15M— | ||
| 0— | 0— | 0— | ||
| 0— | 0— | 0— | ||
| $1K0.0% | $1K-80.0% | $5K— | ||
| $0— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.00— | ||
| 5.1M+2.8% | 5M-63.8% | 13.8M— | ||
| $14.85M-1.6% | $15.09M— | $0— | ||
| $5.54M-1.8% | $5.64M-75.3% | $22.81M— | ||
| $10.79M-27.0% | $14.8M+60.4% | $9.22M— | ||
| $857K— | $0-100% | $2.35M— | ||
| $111K-82.4% | $632K-44.0% | $1.13M— | ||
| $447K-28.9% | $629K-19.4% | $780K— | ||
| $1.88M-5.9% | $2M-79.8% | $9.89M— | ||
| $4.57M+28.8% | $3.54M-34.5% | $5.41M— | ||
| $5.13M+2.8% | $4.99M-63.8% | $13.79M— | ||
| $00.0% | $00.0% | $0— | ||
| $120M0.0% | $120M0.0% | $120M— | ||
| $14.58M+0.7% | $14.48M-69.4% | $47.37M— | ||
| $14.58M+0.7% | $14.48M-69.4% | $47.37M— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| $0.10.0% | $0.1+24.4% | $0.08— | ||
| $328K-29.5% | $465K-7.6% | $503K— | ||
| $448K-30.2% | $642K+142% | $265K— | ||
| $00.0% | $00.0% | $0— | ||
| $15M0.0% | $15M0.0% | $15M— | ||
| $0— | $0— | $0— | ||
| $0— | $0— | $0— | ||
| $1.3M+59.7% | $816K— | —— | ||
| —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Inhibrx Biosciences, Inc.'s total assets?
- Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.
- How much debt does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.
- How much cash does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.
- Can Inhibrx Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 6.46 — current assets exceed current liabilities.
- Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
